Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva's Allergan Generics Buy Progressing, Though Timeline Might Slip

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries Ltd. assured investors that its $40.5bn deal to buy Allergan PLC's generic drug business is progressing as expected during the company's fourth quarter sales and earnings call on Feb. 11, although CEO-Global Generic Medicines Sigurdur Olafsson said the timeline of the closing could slip from the first quarter into the first part of the second.